Evidence map›Paper›PMID 38882256›Full record

ArticleDigital health

PaiNEd app. Assessing central sensitization in survivors of breast cancer: A reliability study.

Miguel Ángel Fernández-Gualda, Patrocinio Ariza-Vega, Noelia Galiano-Castillo, Isabel Tovar-Martín, Lucía Ortiz-Comino, Mario Lozano-Lozano, Carolina Fernández-Lao

Abstract read
In one paragraph

Article in Digital health. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Miguel Ángel Fernández-GualdaBiomedical Group (BIO277), Department of Physical Therapy, Health Sciences Faculty, University of Granada, Granada, Spain.
Patrocinio Ariza-VegaInstituto de Investigación Biosanitaria, Ibs.GRANADA, Granada, Spain.
Noelia Galiano-CastilloBiomedical Group (BIO277), Department of Physical Therapy, Health Sciences Faculty, University of Granada, Granada, Spain.
Isabel Tovar-MartínInstituto de Investigación Biosanitaria, Ibs.GRANADA, Granada, Spain.
Lucía Ortiz-CominoInstituto de Investigación Biosanitaria, Ibs.GRANADA, Granada, Spain.
Mario Lozano-LozanoBiomedical Group (BIO277), Department of Physical Therapy, Health Sciences Faculty, University of Granada, Granada, Spain.ORCID https://orcid.org/0000-0001-5854-3567
Carolina Fernández-LaoBiomedical Group (BIO277), Department of Physical Therapy, Health Sciences Faculty, University of Granada, Granada, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Pain is a common adverse event in survivors of breast cancer (sBCs). As there is no gold standard to assess pain experience predominantly related to central sensitization (CS) symptoms, we designed the Objective: We aimed to assess the reliability of the Methods: An observational, descriptive reliability design was employed to assess the inter- and intrarater reliability of the Results: A total of 21 sBCs with persistent pain were recruited. We observe a general trend of close agreement between the paper-based and app-based formats (ICCs ranged between 0.802 and 0.972; Cronbach's alpha ranged between 0.797 and 0.971). Test-retest reliabilities were moderate to excellent (ICCs ranged between 0.510 and 0.941; Cronbach's alpha ranged between 0.499 and 0.938). The agreement between the categorization of the CS algorithm and the CSI (cut-off point ≥ 40 for CS symptoms) was 95.24%. Conclusion: The

Indexed as

appbreast cancercancer painCentral sensitizationchronic painmHealthmobile healthpersistent painreliability

Identifiers

PMID38882256
PMCPMC11179517

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.